This prospective, open-label study evaluated the efficacy and safety of adjunctive levetiracetam (LEV) in Korean adults with uncontrolled partial epilepsy.
KEYWORDS
Study patients had to have an average of at least 1 and not more than 14 partial seizures per month (averaged over a 3-month historical baseline) despite the use of one or two AEDs. Patients initially received LEV 1000 mg/day (administered bid) and could increase to 2000 mg/day after 2 weeks, and to 3000 mg/day after another 2 weeks, to obtain adequate seizure control. During the 12-week maintenance period, the dose of LEV could be increased or decreased once if seizure control was insufficient or tolerability warranted, respectively. Seizure count and adverse events Introduction Levetiracetam (LEV) is a newer antiepileptic drug (AED) that has been approved as an adjunctive treatment in adults with partial epilepsy in more than 50 countries. LEV has close to ideal pharmacokinetic characteristics, that include high oral bioavailability, linear pharmacokinetics, low plasma protein binding, primary excretion unchanged in urine, and no known clinically significant drug-drug interactions. 1 LEV has a unique pharmacological activity profile in animal models of seizures and epilepsy. 2 The discovery of SV2A as the binding site of LEV in the brain has proven it possesses a mechanism of action distinct from other AEDs. 3 Thus, its clinical efficacy and tolerability profiles may be different from other AEDs.
LEV efficacy was established in double-blind, placebo-controlled trials [4] [5] [6] and effectiveness by indirect comparisons based on meta-analysis which suggest that add-on therapy with LEV has a favourable responder and/or withdrawal rate relative to several new AEDs in patients with partial epilepsy. 7 Multicentre, short-term, open-label, single-arm, add-on trials of LEV also demonstrated its efficacy and safety. [8] [9] [10] LEV seems to be promising in longterm treatment. Recently, Depondt et al. 11 reported experience with LEV treatment of 811 patients with refractory epilepsy including generalized epilepsy and estimated the 3 year retention rate at 58%. Furthermore, long-term, add-on trials of LEV showed seizure freedom for !6 months in 10-30% of patients. [11] [12] [13] [14] [15] [16] The present study, conducted in Korea, further assessed the efficacy and safety of LEV as add-on therapy in patients suffering from partial seizures not adequately controlled despite treatment with up to two other AEDs. The impact of LEV on healthrelated quality of life was also assessed. The protocol used an open-label methodology, very similar to routine clinical practice regarding inclusion criteria and dose escalation.
Methods

Study population
Patients 18 years or older with partial seizures, whether or not secondarily generalized, were eligible for enrolment. Patients must have presented with an average of at least 1 and not more than 14 partial seizures per month (averaged over a 3-month period preceding study entry) despite the use of one or two AEDs. Partial seizures were classified according to the Commission on the Classification and Terminology of the International League against Epilepsy. 17 Patients were allowed one but not more than two concomitant AEDs at the time of study entry, with benzodiazepines being considered as an AED if taken on a daily basis for any indication. The AED regimen was required to have been stable for at least 4 weeks prior to study entry. Patients with mild-to-moderate renal impairment were eligible with appropriate dose adjustment. Patients were excluded if they had conditions expected to unduly complicate management or evaluation. This included serious psychiatric disorder within the past 5 years, uncountable seizures or history of convulsive status epilepticus within the last 5 years, presence of known pseudoseizures within the last year, progressive degenerative neurological disease, previous exposure to LEV, participation in another clinical study with investigational drug or device within 12 weeks of the selection visit, history of questionable compliance to schedule visit or medication intake, pregnant or lactating females and females of childbearing potential unwilling to utilize a medically acceptable birth control method, and visual field defect relevant to vigabatrin as a previous or concomitant AED. began with a 3-month historical baseline period followed by a 16-week treatment period in 9 Korean centres. Prior to initiation, the study was approved by Institutional Review Board of each centre. It was conducted according to ICH guidelines and the Declaration of Helsinki.
Study design
The study was divided into an up-titration period (first 4 weeks) and a maintenance period (last 12 weeks) as shown in Fig. 1 . At visit 1 (week 0), investigators obtained patients' written informed consent, collected demographic data and medical/surgical histories, and performed physical and neurological examinations, including vital signs and body mass. During the 4-week up-titration period, patients initially received LEV 1000 mg/ day (V1) (administered bid). The dose could be increased to 2000 mg/day after 2 weeks (V2) and to 3000 mg/day after an additional 2 weeks (V3) at the discretion of the investigator if it was clinically necessary to achieve maximum benefit. During the 12-week maintenance period LEV dose could be increased at V4 (week 10) in patients who were receiving either of the two lower doses if seizure control was insufficient, and decreased on a single occasion in patients who were receiving either of the two higher doses if poorly tolerated.
At week 16, patients made a fifth and final visit on completion of the study, at which time final data were collected. At this time, patients were also given the opportunity to continue treatment in a separate Named Patient Program as long-term follow-up. Those who elected not to continue had their dose gradually reduced and were seen again 2 weeks after the last dose.
Patients recorded the date, number, and type of seizures on a daily record card; each investigator coded the seizures experienced by his or her patients. Adverse events (AEs) were recorded at each visit based on spontaneous patient reports, investigator observation, responses to a standard question asked by the investigator, and events recorded on the patient daily record card.
Prior and concomitant therapy
The history of previous AEDs was investigated. For the purposes of the study evaluation, the patient's concomitant AEDs had to remain constant during the study, except when medically needed. Additional medication could be prescribed for the well-being of the patient; however, medication (other than AEDs) affecting the central nervous system was to be avoided unless the patient had been on a stable dose for at least the last 6 months before the first visit. Concomitant medication remained at the same stable dose throughout the study.
Efficacy and safety measurements
Efficacy end points were based on the frequency of seizures during the 16-week treatment period (titration and maintenance) compared with the 3-month baseline period as well as retention rate. The primary efficacy variables were the percent reduction from baseline in seizure frequency per week and the retention rate at week 16, defined as the number of subjects still treated with LEV at the end of 16-week treatment period divided by the number of patients in the intent-to-treat (ITT) population. Other efficacy variables included the absolute reduction in the frequency of partial seizures per week, the responder rates and the number of seizurefree patients. For patients who did not complete the 16-week treatment period, data up to withdrawal were used in the analysis of efficacy.
Other variables included global evaluation of disease evolution and quality of life. A validated Korean version of the original Quality of Life in Epilepsy Questionnaire (QOLIE-31) instrument 18, 19 was filled in at the selection visit and at the end of the 16-week treatment period or upon early withdrawal. Following the completion of treatment, the investigator provided a global evaluation scale (GES) to assess the overall change in the severity of the patient's illness compared to the start of study medication. The rating was based on overall clinical impression (marked improvement, moderate improvement, slight improvement, no change, slight worsening, moderate worsening, and marked worsening). Safety was assessed by AEs, physical and neurological examination, and laboratory evaluation at visit 1 (week 0) and visit 5 (week 16). Physical examinations included measurement of vital signs and an electrocardiogram (ECG). The analyses were done on the ITT population.
Statistical methods
Safety analyses were performed on the intent-totreat (ITT) population, which included all patients who took at least one dose of LEV. However, three patients who discontinued the study at the early stage without any post-treatment seizure count did not contribute into the efficacy analyses based on seizure count during the treatment period. Study variables were summarized by descriptive statistics: mean, median, standard deviation, Q1 and Q3, range for continuous variables and frequency tables for categorical variables. Baseline characteristics (gender, age, aetiology of epilepsy, history of epilepsy, previous and concomitant AEDs) and LEV exposure were summarized descriptively for the ITT population.
Results
Demographics
A total of 100 patients were enrolled and formed the ITT population (Table 1) . Of these, 52 (52.0%) were male and 48 (48.0%) were female. Patients' ages ranged from 17 to 72 years, with a mean age (AES.D.) of 35.3 (AE11.7) years. All patients were Korean. The mean age (AES.D.) at onset of epilepsy was 17.8 (AE12.3) years and the mean duration (AES.D.) of epilepsy was 17.4 (AE9.5) years. The aetiology of epilepsy was unknown in 49% of patients or attributed to cerebral infection (14%), hippocampal sclerosis without a history of significant brain insult (13%), cranial trauma (8%), malformation of cortical development (4%), atrophic change including cerebromalacia or cyst without a history of significant brain insult (4%), cavernous haemangioma (2%), cerebral neoplasm (2%), cerebral infarction (1%), brain surgery (1%), perinatal hypoxia (1%), and tuberous sclerosis (1%). The median (Q1-Q3) baseline seizure frequency was 0.62 (0.39-1.09) per week. Eighty patients presented with at least one complex partial seizure, 28 patients with at least 1 a One patient was 17-year-old but the data was included until she was withdrawn from the study.
b Six patients who were regarded as receiving two AEDs plus benzodiazepines used as an anxiolytic (classified as a third AED in this protocol), were included in the study.
secondarily generalized tonic-clonic seizure, and 13 patients with at least 1 simple partial seizure during the baseline 3-month period. In the history of previous AED treatment, 76 patients had taken two or more AEDs prior to entry to this study. The majority (80%) of patients entered the trial on two concomitant AEDs. Six patients were receiving two AEDs plus benzodiazepines used as anxiolytics (classified as a third AED in this protocol); these patients were included in the study because anxiolytics were not considered to affect the study result. The most frequently used concomitant AEDs were carbamazepine, valproic acid, lamotrigine, and topiramate.
Of the 100 patients, 92 (92.0%) completed the 16-week treatment and 8 discontinued the study. Four patients withdrew due to an AE, one withdrew because of a lack of efficacy, and three withdrew for other reasons (withdrawal of consent in two and violation of inclusion criteria in one). The trial began on 
Efficacy
As three patients discontinued the study (withdrawal of consent in two patients and AE in one patient) without providing any seizure count after baseline, they did not contribute into the efficacy analysis. Ninety-seven patients were analysed. Overall, 72 patients (74%) experienced a reduction from baseline in seizure frequency per week throughout the study period. In the ITT population, the median (Q1-Q3) percent reduction in seizure frequency was 43.2% (Q1-Q3, 0.4-84.8%) over the entire treatment period (range, À812.5 to 100.0%). The frequency of seizures decreased from a median (Q1-Q3) of 0.62 (Q1-Q3: 0.39-1.09) per week over the baseline period to 0.36 (Q1-Q3: 0.06-0.79) per week over treatment period in the study. The decrease in median seizure frequency was already apparent following the initial 2 weeks of titration, when all patients received 1000 mg/day, and was maintained throughout the treatment phase. The median seizure frequency was 0.00 per week during the initial 2 weeks (n = 96, median reduction from baseline = 100%), remained at 0.00 per week during week 2-4 (n = 96, median reduction from baseline = 100%), then was 0.33 per week during week 4-10 (n = 96, median reduction from baseline = 48.33%) and remained at 0.33 during the last 6 weeks (n = 92, median reduction from baseline = 50.18%) as shown in Fig. 2 .
Over the entire treatment period, 45.4% (44/97) of patients had a 50% or greater reduction in seizures count, 36.1% (35/97) had at least a 75% reduction, and 18.6% (18/97) of patients had a 100% reduction; seizure freedom was obtained only for 4 weeks in 1 patient who was found to have a brain tumour during the trial and discontinued the trial. During the last 12 weeks, 49.5% (48/97) of patients had a 50% or greater reduction, 34.0% (33/97) had a 75% or greater reduction, and 22.7% (22/97) of patients had a 100% reduction.
At V4 (week 10) the LEV dose was increased up to 3000 mg in 13 patients because of insufficient seizure control; 2 patients had a 75% or greater reduction and a reduction of 50% or greater but less than 75%, respectively and the remaining 11 patients had less than 50% reduction over the 16-week treatment.
Global evaluation scale and QOLIE-31 (ITT population)
Improvement (marked, 41%; moderate, 16%; slight, 24%) reported by the investigator was observed in 81% of patients, no change in 16%, and worsening (slight) in 3%. No cases of moderate or marked worsening of the disease were reported by investigators. All QOLIE-31 scales, the total score, and health status item improved. Statistically significant changes were reached for all but energy/fatigue and medication effects ( Table 2) . Of the 95 patients evaluable for quality of life analysis, 66 (69.5%) experienced improvement in their overall QOLIE-31.
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Safety
One hundred and thirteen treatment-emergent AEs were reported in 59 patients. AEs that emerged in 3% or more of patients during the treatment period are listed in Table 3 . The three most commonly reported AEs were somnolence (36%), dizziness (12%), and headache (8%). The majority (96%) of treatment-emergent AEs were mild to moderate in intensity. Nine patients reported AEs leading to temporary discontinuation or dose modification of LEV. Four patients discontinued the trial due to AEs; three patients had AEs that were considered by the investigator to be related to LEV treatment (somnolence, headache, and abdominal pain, each in one subject) and one patient was diagnosed as having brain tumour during the trial, that was not considered to be related to LEV treatment. Four patients experienced serious AEs (brain tumour, abnormal behaviour, back pain due to traffic accident, and inguinal hernia). Among them, there was a patient with abnormal behaviour which was considered to be related to LEV, leading to temporary discontinuation of LEV. The other serious AEs were not considered to be related to LEV treatment. Psychiatric AEs occurred in five patients (abnormal behaviour and insomnia, anxiety, and nervousness, respectively, in three individual patients, and depression in two patients).
Neurological examination revealed nervous system abnormalities in 10% of patients at baseline and no relevant change was observed overall during treatment, with the exception of one subject who developed slight right hemiparesis due to a brain tumour. Body weight increases of at least 7% from baseline occurred in five patients (range >4 to >10 kg; representing a weight increase of 7.1-18.0% from baseline), and decreases of at least 7% occurred in another 10 patients (range À4 to À10 kg; representing a weight decrease of À7.0 to À15.3% from baseline). Three patients had a weight increase larger than 10% and 3 patients had a weight decrease larger than 10%. For only one patient showing decrease, weight change was reported as an AE.
During the course of the 16-week treatment, no clinically significant changes were observed on ECG, and minimal changes were observed in the vital signs. Abnormal blood pressure (BP) was reported in five patients. Diastolic BP decreased in two patients, systolic BP decreased in one patient, and both systolic and diastolic BP decreased in two patients having possibly clinical significant (PCS) values (systolic BP, 90 mm Hg and a decrease from baseline of !30 mm Hg; diastolic BP, 50 mm Hg and a decrease from baseline of !20 mm Hg). PCS abnormalities in laboratory values were observed in 18 patients. However, in 10 patients, these abnormalities were already present at baseline. The remaining 8 patients had 10 treatmentemergent PCS abnormalities not present at baseline: decreased estimated creatinine clearance in 3 patients, decreased haematocrit in 3 patients, and decreased haemoglobin, white blood cells and serum glucose, and increased eosinophils in 4 individual patients.
Discussion
This multicentre open-label study with levetiracetam was designed to bridge with a similar study on Caucasian epileptic subjects 20 before authorization in Korea. The design of this study was similar to a post-marketing, open-label, add-on study in patients with inadequately controlled partial-onset seizures that was conducted in 1030 patients from over 300 neurological practices in the US (The KEE-PER  TM trial  8 ) . However, the present study was more similar to community-based clinical practice in that AED doses could be increased with more flexibility and patients with less severe epilepsy (low baseline seizure frequency) were recruited. The median baseline seizure frequency in this study was 0.62 per week which was less than in other multicentre, short-term, open-label, single-arm, add-on trials of similar methodology (3.7 per month in the KEEPER TM trial, 8 2.25 per week in a study by Abou-Khalil et al. 9 and 2.3 per week in a study by Beran et al. 10 ).
Similarly to other open-label, short-term trials, the results of the Korean open-label trial confirm the results derived from placebo-controlled, blinded clinical trials. [8] [9] [10] In the 16-week treatment, LEV reduced the weekly frequency of seizures by a median of 43.2%. A total of 72 patients (74%) experienced a reduction from baseline in seizure count; 17 patients became seizure-free from the first day and remained so throughout the 16-week of treatment period, 45.4% of patients experienced a reduction in seizures of !50% and 36.1% had a reduction of 75% or greater.
The decrease in seizures was also reflected in subjective measures of improvement in the present study. The global evaluation scale showed disease improvement in 81% of patients as determined by the investigator with an overall improvement in health-related quality of life reported in almost 70% of patients.
This study also provides support for LEV's safety confirming the known good safety profile. One hundred and thirteen treatment-emergent AEs were reported in 59 patients but only four patients were withdrawn due to AEs (three related to LEV treatment). The withdrawal rate due to AEs in this study is lower compared with those of the pooled data from double-blind, placebo-controlled studies 21 and of two trials 8, 9 of similar methodology (8-13%) but comparable to those of another trial 10 of similar methodology (2%) and a placebo-controlled trial 22 performed in Taiwanese patients (6%).
The commonly reported AEs were somnolence, dizziness, headache and fatigue. A higher incidence of somnolence was observed in the present study compared with reports of somnolence in the pooled data from double-blind, placebo-controlled studies 21 (36% versus 15%), while a lower incidence of fatigue and headache were reported (7% versus 15% and 8% versus 14%, respectively). The rates of dizziness (12% versus 9%) were comparable. The incidence of somnolence in this study was also much higher in comparison with that in the three open-label, short-term, trials (11-21%) [8] [9] [10] but agrees with that (40%) of a placebo-controlled trial performed in Taiwanese patients, that used LEV of up to 2000 mg per day but allowed one to three concomitant AEDs. 22 The Taiwanese study suggested that the high incidence of somnolence might be related to the greater number of concomitant AEDs. In this study, it might be related to the use of relatively higher doses of LEV in Oriental patients with lower body weight compared with Western patients. However, this study showed lower or similar frequencies in fatigue, headache, and dizziness that are generally known to be dosedependant with most AEDs. Therefore racial difference might affect the incidence of somnolence. Experience with LEV therapy in a larger number of Oriental patients will be necessary to understand this difference.
This study demonstrated that LEV is effective and well tolerated in adult Korean subjects with uncontrolled partial epilepsy when administered at optimized doses ranging from 1000 to 3000 mg/day, as evidenced by the high seizure free and retention rates. The results of this study are also consistent with those reported in Phase III controlled studies and other open-label, single-arm trials.
Conclusions
LEV administered as adjunctive therapy in Korean adults with refractory partial epilepsy was effective and generally well-tolerated, as evidenced by the high seizure free and retention rates in the 16-week treatment.
